{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:34:29Z","timestamp":1790847269785,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Somatic mutations in the calreticulin (\n                    <jats:italic>CALR<\/jats:italic>\n                    ) gene are associated with approximately 30% of essential thrombocythemia (ET) and primary myelofibrosis (PMF).\n                    <jats:italic>CALR<\/jats:italic>\n                    mutations, including the two most frequent 52\u2009bp deletion (\n                    <jats:italic>del52<\/jats:italic>\n                    ) and 5\u2009bp insertion (\n                    <jats:italic>ins5<\/jats:italic>\n                    ), induce a frameshift to the same alternative reading frame generating new C-terminal tails. In patients,\n                    <jats:italic>del52<\/jats:italic>\n                    and\n                    <jats:italic>ins5<\/jats:italic>\n                    induce two phenotypically distinct myeloproliferative neoplasms (MPNs). They are equally found in ET, but\n                    <jats:italic>del52<\/jats:italic>\n                    is more frequent in PMF. We generated heterozygous and homozygous conditional inducible knock-in (KI) mice expressing a chimeric murine CALR del52 or ins5 with the human mutated C-terminal tail to investigate their pathogenic effects on hematopoiesis. Del52 induces greater phenotypic changes than ins5 including thrombocytosis, leukocytosis, splenomegaly, bone marrow hypocellularity, megakaryocytic lineage amplification, expansion and competitive advantage of the hematopoietic stem cell compartment. Homozygosity amplifies these features, suggesting a distinct contribution of homozygous clones to human MPNs. Moreover, homozygous\n                    <jats:italic>del52<\/jats:italic>\n                    KI mice display features of a penetrant myelofibrosis-like disorder with extramedullary hematopoiesis linked to splenomegaly, megakaryocyte hyperplasia and the presence of reticulin fibers. Overall, modeling\n                    <jats:italic>del52<\/jats:italic>\n                    and\n                    <jats:italic>ins5<\/jats:italic>\n                    mutations in mice successfully recapitulates the differences in phenotypes observed in patients.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-18691-3","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T06:03:30Z","timestamp":1601273010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN"],"prefix":"10.1038","volume":"11","author":[{"given":"Cam\u00e9lia","family":"Benlabiod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira da Costa","family":"Cacemiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"N\u00e9d\u00e9lec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Edmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rameau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Touchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-4580","authenticated-orcid":false,"given":"Patrick","family":"Gonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-2699","authenticated-orcid":false,"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Raslova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Villeval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-202X","authenticated-orcid":false,"given":"William","family":"Vainchenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Plo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4350-2302","authenticated-orcid":false,"given":"Caroline","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"18691_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"18691_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391\u20132405 (2013).","journal-title":"N. Engl. J. Med."},{"key":"18691_CR3","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379\u20132390 (2013).","journal-title":"N. Engl. J. Med."},{"key":"18691_CR4","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).","journal-title":"PLoS Med."},{"key":"18691_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","volume":"127","author":"I Chachoua","year":"2016","unstructured":"Chachoua, I. et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127, 1325\u20131335 (2016).","journal-title":"Blood"},{"key":"18691_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf, S. et al. Mutant calreticulin requires both its mutant c-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 6, 368\u2013381 (2016).","journal-title":"Cancer Discov."},{"key":"18691_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/leu.2014.270","volume":"29","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols, X. et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29, 249\u2013252 (2015).","journal-title":"Leukemia"},{"key":"18691_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty, C. et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 127, 1317\u20131324 (2016).","journal-title":"Blood"},{"key":"18691_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41388-018-0538-z","volume":"38","author":"KR Toppaldoddi","year":"2019","unstructured":"Toppaldoddi, K. R. et al. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene 38, 1651\u20131660 (2019).","journal-title":"Oncogene"},{"key":"18691_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/leu.2016.308","volume":"31","author":"K Shide","year":"2017","unstructured":"Shide, K. et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia 31, 1136\u20131144 (2017).","journal-title":"Leukemia"},{"key":"18691_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0202-z","volume":"9","author":"K Shide","year":"2019","unstructured":"Shide, K. et al. Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. Blood Cancer J. 9, 42 (2019).","journal-title":"Blood Cancer J."},{"key":"18691_CR12","doi-asserted-by":"crossref","unstructured":"Balligand, T. et al. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia 34, 510\u2013521 (2020).","DOI":"10.1038\/s41375-019-0538-1"},{"key":"18691_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","volume":"131","author":"J Li","year":"2018","unstructured":"Li, J. et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood 131, 649\u2013661 (2018).","journal-title":"Blood"},{"key":"18691_CR14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/leu.2016.47","volume":"30","author":"T Balligand","year":"2016","unstructured":"Balligand, T. et al. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. Leukemia 30, 1775\u20131778 (2016).","journal-title":"Leukemia"},{"key":"18691_CR15","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/leu.2017.112","volume":"31","author":"T Maekawa","year":"2017","unstructured":"Maekawa, T. et al. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis. Leukemia 31, 2709\u20132716 (2017).","journal-title":"Leukemia"},{"key":"18691_CR16","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am. J. Hematol. 89, E121\u2013E124 (2014).","journal-title":"Am. J. Hematol."},{"key":"18691_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra, D. et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30, 431\u2013438 (2016).","journal-title":"Leukemia"},{"key":"18691_CR18","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.3324\/haematol.2018.202952","volume":"104","author":"A Stengel","year":"2019","unstructured":"Stengel, A. et al. Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease. Haematologica 104, e187\u2013e190 (2019).","journal-title":"Haematologica"},{"key":"18691_CR19","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1038\/s41388-020-1368-3","volume":"39","author":"M El-Khoury","year":"2020","unstructured":"El-Khoury, M. et al. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene 39, 5323\u20135337 (2020).","journal-title":"Oncogene"},{"key":"18691_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi, E. et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123, 1544\u20131551 (2014).","journal-title":"Blood"},{"key":"18691_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2016.280","volume":"31","author":"K Kollmann","year":"2017","unstructured":"Kollmann, K. et al. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia 31, 934\u2013944 (2017).","journal-title":"Leukemia"},{"key":"18691_CR22","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2016-02-696310","volume":"127","author":"APA Theocharides","year":"2016","unstructured":"Theocharides, A. P. A. et al. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood 127, 3253\u20133259 (2016).","journal-title":"Blood"},{"key":"18691_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","volume":"77","author":"P Liu","year":"2020","unstructured":"Liu, P. et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol. Cell 77, 748\u2013760.e9 (2020).","journal-title":"Mol. Cell"},{"key":"18691_CR24","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.1074\/jbc.RA118.002836","volume":"293","author":"N Arshad","year":"2018","unstructured":"Arshad, N. & Cresswell, P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J. Biol. Chem. 293, 9555\u20139569 (2018).","journal-title":"J. Biol. Chem."},{"key":"18691_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","volume":"32","author":"MO Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m, M. O. et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32, 429\u2013437 (2018).","journal-title":"Leukemia"},{"key":"18691_CR26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","volume":"9","author":"C Cimen Bozkus","year":"2019","unstructured":"Cimen Bozkus, C. et al. Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov. 9, 1192\u20131207 (2019).","journal-title":"Cancer Discov."},{"key":"18691_CR27","first-page":"106","volume":"136","author":"K Shide","year":"2020","unstructured":"Shide, K. et al. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood 136, 106\u2013118 (2020).","journal-title":"Blood"},{"key":"18691_CR28","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.4049\/jimmunol.176.11.6425","volume":"176","author":"O Wagner-Ballon","year":"2006","unstructured":"Wagner-Ballon, O. et al. Monocyte\/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. J. Immunol. 176, 6425\u20136433 (2006).","journal-title":"J. Immunol."},{"key":"18691_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/dvg.20826","volume":"50","author":"M-C Birling","year":"2012","unstructured":"Birling, M.-C., Dierich, A., Jacquot, S., H\u00e9rault, Y. & Pavlovic, G. Highly-efficient, fluorescent, locus directed cre and FlpO deleter mice on a pure C57BL\/6N genetic background. Genesis 50, 482\u2013489 (2012).","journal-title":"Genesis"},{"key":"18691_CR30","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2004-08-3037","volume":"105","author":"JR G\u00f6thert","year":"2005","unstructured":"G\u00f6thert, J. R. et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood 105, 2724\u20132732 (2005).","journal-title":"Blood"},{"key":"18691_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1895","volume":"214","author":"BC Schaefer","year":"2001","unstructured":"Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P. & Kedl, R. M. Observation of antigen-dependent CD8+ T-cell\/ dendritic cell interactions in vivo. Cell. Immunol. 214, 110\u2013122 (2001).","journal-title":"Cell. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18691-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:03:28Z","timestamp":1670270608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18691-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18691"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18691-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"15 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4886"}}